Vera Therapeutics, Inc. (VERA) key performance indicators and operating metrics (6 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Hematuria resolution: atacicept and placebo | 81.00 percent | FY2026-Q2 |
| Galactose-deficient immunoglobulin A1 reduction: atacicept and placebo | 68.00 percent | FY2026-Q2 |
| Proteinuria reduction | 46.00 percent | FY2026-Q2 |
| Galactose-deficient immunoglobulin A1 reduction versus placebo | 67.00 percent | FY2025-Q3 |
| Mean urine protein-to-creatinine ratio percentage reduction versus placebo: subgroup analyses | 42.00 percent | FY2025-Q2 |
| Therapeutics operating income | -83.93M | FY2025-Q3 |
Back to VERA overview · VERA earnings · VERA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.